

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal617sxw

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	May 12	EXTEND option available in structure searching
NEWS	4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in Caplus
NEWS	6	May 27	Caplus super roles and document types searchable in REGISTRY
NEWS	7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12	AUG 02	Caplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS	16	AUG 27	BIOCOMMERCE: Changes and enhancements to content coverage
NEWS	17	AUG 27	BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS	18	SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS	19	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	20	SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS	21	SEP 14	STN Patent Forum to be held October 13, 2004, in Iselin, NJ
NEWS EXPRESS		JULY 30	CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:59:07 ON 20 SEP 2004

=> file caplus medline biosis

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 13:59:21 ON 20 SEP 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 13:59:21 ON 20 SEP 2004

FILE 'BIOSIS' ENTERED AT 13:59:21 ON 20 SEP 2004

Copyright (c) 2004 The Thomson Corporation.

=> s croft-j?/au

L1 466 CROFT-J?/AU

=> s l1 and new (w) zealand

L2 2 L1 AND NEW (W) ZEALAND

=> d ibib abs 1-2

L2 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:889642 CAPLUS

DOCUMENT NUMBER: 134:21423

TITLE: A synergistic composition comprising mussel protein extract and glycosaminoglycan suitable for treatment of arthritis

INVENTOR(S): Croft, John Eric

PATENT ASSIGNEE(S): MacFarlane Laboratories New Zealand Limited, N. Z.

SOURCE: Brit. UK Pat. Appl., 10 pp.

CODEN: BAXXDU

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2347349	A1	20000906	GB 1999-4672	19990301
PRIORITY APPLN. INFO.:			GB 1999-4672	19990301

AB A pharmaceutical composition comprising proteins extracted from the New Zealand green-lipped mussel (*Perna canaliculus*) and one or more glycosaminoglycans, preferable glucosamine or its sulfate, has anti-inflammatory properties. The composition is used in the treatment of arthritis. The combination of the protein extract and the glycosaminoglycan is synergistic with respect to the effect of the same concentration of the individual components. The preferred composition included a homogeneous mixture of a freeze-dried powder containing protein extract and glycosaminoglycan powder. The compns. are capsules or tablets.

L2 ANSWER 2 OF 2 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

ACCESSION NUMBER: 1993:438586 BIOSIS

DOCUMENT NUMBER: PREV199396093211

TITLE: The independent effects of obesity and body fat distribution on blood pressure in black adults: The Pitt County study.

AUTHOR(S): Croft, Janet B.; Strogatz, David S.; Keenan, Nora
L.; James, Sherman A. [Reprint author]; Malarcher, Ann M.;
Garrett, Joanne M.
CORPORATE SOURCE: Univ. Mich., Dep. Epidemiology, Sch. Public Health, 109
Observatory Street, Ann Arbor, MI 48109, USA
SOURCE: International Journal of Obesity, (1993) Vol. 17, No. 7,
pp. 391-397.
CODEN: IJOB DP. ISSN: 0307-0565.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 22 Sep 1993
Last Updated on STN: 22 Sep 1993

AB The relationship of obesity measures to blood pressure and hypertension prevalence was assessed in a community probability sample of 25-50-year-old black adults (1101 women and 655 men) who were examined in 1988 in Pitt County, North Carolina (USA). Among black women, both body mass index and waist-to-hip ratio had independent relationships with systolic and diastolic blood pressures and hypertension prevalence after controlling for the effects of age, socio-economic status, physical activity, alcohol, and the other obesity measure ($P < 0.05$). Body mass index also had independent relationships with blood pressure levels and hypertension prevalence in black men ($P < 0.05$), while waist-to-hip ratio was associated with hypertension prevalence ($P = 0.05$) and diastolic blood pressure ($P < 0.05$), but not with systolic blood pressure. The relationships of waist-to-hip ratio with blood pressure and hypertension prevalence were considerably reduced in both sex groups after controlling for body mass index. This study presents new evidence that waist-to-hip ratio is related to hypertension and blood pressure level independent of body mass index, in young to middle-aged black adult women and men.

=> s l1 and perna
L3 2 L1 AND PERNA

=> s l3 not l2
L4 1 L3 NOT L2

=> d ibib abs

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1980:573751 CAPLUS
DOCUMENT NUMBER: 93:173751
TITLE: Pharmaceutical preparations containing a mollusk
extract
INVENTOR(S): McFarlane, Stuart John; Croft, John Eric
PATENT ASSIGNEE(S): N. Z.
SOURCE: Eur. Pat. Appl., 34 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 10061	A1	19800416	EP 1979-810098	19790919
EP 10061	B1	19830713		
R: BE, CH, DE, FR, GB, IT, LU, NL, SE				
WO 8000661	A1	19800417	WO 1979-EP72	19790920
W: DE, SE, US				
DE 2953186	T	19810108	DE 1979-2953186	19790920
CA 1134745	A1	19821102	CA 1979-336104	19790921
IL 58301	A1	19821130	IL 1979-58301	19790921
AU 7951107	A1	19800403	AU 1979-51107	19790924
AU 536153	B2	19840419		

ZA 7905039	A	19800924	ZA 1979-5039	19790924
JP 55147223	A2	19801117	JP 1979-122127	19790925
US 4455298	A	19840619	US 1982-376898	19820510
PRIORITY APPLN. INFO.:			NZ 1978-188489	19780925
			WO 1979-EP72	19790920
			US 1980-194152	19800915

AB The occurrence of gastric ulcers or stomach bleeding from drugs is inhibited by combination with the drugs of a mollusk **Perna canaliculus** extract (Seatone), which is composed of proteins, carbohydrates and minerals (mineral and amino acid content given). Capsule compns. were given containing the extract and analgesics-inflammation inhibitors such as acetylsalicylic acid [50-78-2], diclofenac Na [15307-79-6], phenylbutazone [50-33-9], or indomethacin [53-86-1].

=> s Perna (w) canaliculus
L5 238 PERNA (W) CANALICULUS

=> s l5 and arthritis
L6 24 L5 AND ARTHRITIS

=> s l6 and chondroitin
L7 1 L6 AND CHONDROITIN

=> d ibib abs

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:889642 CAPLUS

DOCUMENT NUMBER: 134:21423

TITLE: A synergistic composition comprising mussel protein extract and glycosaminoglycan suitable for treatment of **arthritis**

INVENTOR(S): Croft, John Eric

PATENT ASSIGNEE(S): MacFarlane Laboratories New Zealand Limited, N. Z.

SOURCE: Brit. UK Pat. Appl., 10 pp.

CODEN: BAXXDU

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	----	-----	-----
GB 2347349	A1	20000906	GB 1999-4672	19990301
PRIORITY APPLN. INFO.:			GB 1999-4672	19990301

AB A pharmaceutical composition comprising proteins extracted from the New Zealand green-lipped mussel (**Perna canaliculus**) and one or more glycosaminoglycans, preferable glucosamine or its sulfate, has anti-inflammatory properties. The composition is used in the treatment of **arthritis**. The combination of the protein extract and the glycosaminoglycan is synergistic with respect to the effect of the same concentration of the individual components. The preferred composition includes ma

homogeneous mixture of a freeze-dried powder containing protein extract and glycosaminoglycan powder. The compns. are capsules or tablets.

=> s shark (w) cartilage
L8 502 SHARK (W) CARTILAGE

=> s l8 and l6
L9 0 L8 AND L6

=> s l8 and arthritis
L10 14 L8 AND ARTHRITIS

=> duplicate remove l10
 DUPLICATE PREFERENCE IS 'CAPLUS, MEDLINE, BIOSIS'
 KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
 PROCESSING COMPLETED FOR L10
 L11 13 DUPLICATE REMOVE L10 (1 DUPLICATE REMOVED)

=> d ibib abs 1-13

L11 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:173639 CAPLUS
 DOCUMENT NUMBER: 138:217168
 TITLE: Serine protease inhibitory glycoprotein from
shark cartilage and therapeutic uses
 INVENTOR(S): Dupont, Eric; Beliveau, Richard; Gingras, Denis;
 Renaud, Alain; Cadoret, France; Dimitriadou, Violetta;
 Falardeau, Pierre
 PATENT ASSIGNEE(S): Les Laboratoires Aeterna Inc., Can.
 SOURCE: PCT Int. Appl., 58 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003018620	A2	20030306	WO 2002-CA1309	20020823
WO 2003018620	A3	20030821		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003100089	A1	20030529	US 2002-228830	20020827

PRIORITY APPLN. INFO.: US 2001-315112P P 20010827
 AB The present invention relates generally to a glycoprotein isolated from
shark cartilage having an apparent mol. weight of about 54
 kDa (p54), which has serine protease inhibitor activity (a serpin-like
 mol.). The p54 glycoprotein has a protein backbone of about 46 kDa
 (hereinafter referred to as "p46 protein" or "p46"). The invention also
 relates to a process for preparing the same, methods as well as compns. for
 treating, preventing or alleviating the symptoms of disorders and diseases
 associated with an excess level of serine protease. Amongst these diseases
 are psoriasis, emphysema, pulmonary hypertension, liver fibrosis, anemia,
 diseases characterized by tumor growth or invasion, as well as any disease
 involving mast-cells. According to another embodiment, the present
 invention provides for antibodies directed specifically against p54 or p46
 and methods for detecting p54 or p46 by using these specific antibodies.
 The activity of p54 towards other types of proteases in addition to elastases
 (PPE and HLE) revealed that p54 also inhibits to a lesser extent other
 serine proteinases such as chymotrypsin (53 %), plasmin (49 %) and trypsin
 (30 %), whereas it does not inhibit MMP-2 and MMP-7, cathepsin D,
 cathepsin G, thrombin and papain (see table III).

L11 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:989927 CAPLUS
 DOCUMENT NUMBER: 140:19891
 TITLE: Compositions for treatment of diseases arising from

secretion of mast cell biochemicals
 INVENTOR(S): Theoharides, Theoharis C.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of U.S.
 Ser. No.773,576.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003232100	A1	20031218	US 2003-439301	20030516
US 6689748	B1	20040210	US 1998-56707	19980408
PRIORITY APPLN. INFO.:			US 1998-56707	A3 19980408
			US 2001-773576	A2 20010202

AB Compsns. for treatment of diseases arising from products secreted by activated tissue mast cells, composed of, as active ingredients, unprocessed olive kernel (pit) extract that increases absorption of these compsns. in various routes of administration, and one or more of a heavily sulfated, non-bovine proteoglycan such as **shark cartilage** chondroitin sulfate C, a hexosamine sulfate such as D-glucosamine sulfate, a flavonoid such as quercetin, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, a CRH antagonist, caffeine, fragments of myelin basic protein, rutin, polyunsatd. fatty acids, Bitter Willow Extract and a polyamine.

L11 ANSWER 3 OF 13 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

ACCESSION NUMBER: 2004:7340 BIOSIS
 DOCUMENT NUMBER: PREV200400008315
 TITLE: Proteoglycan compositions for treating arthritic inflammatory conditions.
 AUTHOR(S): Theoharides, Theoharis C. [Inventor, Reprint Author]
 PATENT INFORMATION: US 6645482 November 11, 2003
 SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Nov 11 2003) Vol. 1276, No. 2.
<http://www.uspto.gov/web/menu/patdata.html>. e-file.
 ISSN: 0098-1133 (ISSN print).
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 ENTRY DATE: Entered STN: 17 Dec 2003
 Last Updated on STN: 17 Dec 2003

AB Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, composed of a heavily sulfated, non-bovine proteoglycan such as **shark cartilage** chondroitin sulfate C, and one or more of a hexosamine sulfate such as D-glucosamine sulfate, a flavone such as quercetin, an unrefined olive kernel extract that increases absorption of these compositions in various routes of administration, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, caffeine, and a polyamine.

L11 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:121318 CAPLUS
 DOCUMENT NUMBER: 141:179397
 TITLE: Anti-arthritis effect of a new diet-supplement containing red ginseng extract and glucosamine complex
 AUTHOR(S): Jeong, Choon Sik; Hyun, Jin Ee; Kang, Min Hee; Sim, Joon-Soo; Son, Mi Jin; Jung, Sang Hoon; Kim, Jong Hoon; Lee, Kwang-Seong; Kim, Yeong Shik

CORPORATE SOURCE: College of Pharmacy, Duksung Women's University,
Seoul, 132-714, S. Korea
SOURCE: Saengyak Hakhoechi (2003), 34(4), 327-334
CODEN: SYHJAM; ISSN: 0253-3073
PUBLISHER: Korean Society of Pharmacognosy
DOCUMENT TYPE: Journal
LANGUAGE: Korean

AB We evaluated the anti-arthritic effect of a new diet-supplement product containing red ginseng, glucosamine, **shark cartilage**, ascorbic acid and manganese chloride for the relieving arthritic symptoms. Anti-inflammatory activities of the aqueous extract of red ginseng (250 and 500 mg/kg), glucosamine (240 mg/kg) and **shark cartilage** (240 mg/kg) were tested individually on vascular permeability and carrageenan-induced paw edema. Glucosamine and **shark cartilage** showed the inhibition of vascular permeability by 29.6 and 32.9%, resp. Red ginseng (500 mg/kg) and **shark cartilage** showed the inhibition of carrageenan-induced paw edema at 0.5, 1, 2 and 3 h. The supplement (red ginseng mixture: RGM) composed of red ginseng (43.5%), glucosamine (25.0%), **shark cartilage** (25.0%), ascorbic acid (5.0%) and manganese chloride (1.5%) was prepared and its inhibitory activities including vascular permeability and carrageenan-induced paw edema were comparable to anti-inflammatory drugs such as diclofenac and ibuprofen. It was also tested on adjuvant-induced **arthritis** in rats as one of chronic arthritic tests and Randall-Selitto assay as an analgesic test. RGM showed the inhibition against the swelling of rat paws induced by Mycobacterium tuberculosis at a dose of 1,500 mg/kg. Determination of cytokines of the sera sampled from **arthritis**-induced animals indicated that RGM increased the levels of interferon- γ and interleukin-6, representing the immunostimulatory effect by red ginseng. RGM treatment moderately reduced the production of NO in RAW 264.7 cells in a dose-dependent manner. Taken together, these results support that RGM can be applicable for the improvement of arthritic symptoms as a new diet-supplement.

L11 ANSWER 5 OF 13 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN

ACCESSION NUMBER: 2003:578098 BIOSIS
DOCUMENT NUMBER: PREV200300583728
TITLE: Clinical implications of matrix metalloproteinases.
AUTHOR(S): Mandal, Malay; Mandal, Amritlal; Das, Sudip; Chakraborti, Tapati; Chakraborti, Sajal [Reprint Author]
CORPORATE SOURCE: Department of Biochemistry and Biophysics, University of Kalyani, Kalyani, West Bengal, 741235, India
s_chakraborti@hotmail.com
SOURCE: Molecular and Cellular Biochemistry, (October 2003) Vol. 252, No. 1-2, pp. 305-329. print.
ISSN: 0300-8177 (ISSN print).
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 10 Dec 2003
Last Updated on STN: 10 Dec 2003

AB Matrix metalloproteinases (MMPs) are a family of neutral proteinases that are important for normal development, wound healing, and a wide variety of pathological processes, including the spread of metastatic cancer cells, arthritic destruction of joints, atherosclerosis, pulmonary fibrosis, emphysema and neuroinflammation. In the central nervous system (CNS), MMPs have been shown to degrade components of the basal lamina, leading to disruption of the blood brain barrier and to contribute to the neuroinflammatory responses in many neurological diseases. Inhibition of MMPs have been shown to prevent progression of these diseases. Currently, certain MMP inhibitors have entered into clinical trials. A goal to the future should be to design selective synthetic inhibitors of MMPs that have minimum side effects. MMP inhibitors are designed in such a way that these can not only bind at the active site of the proteinases but also to

have the characteristics to bind to other sites of MMPs which might be a promising route for therapy. To name a few: catechins, a component isolated from green tea; and Novastal, derived from extracts of **shark cartilage** are currently in clinical trials for the treatment of MMP-mediated diseases.

L11 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:594640 CAPLUS
 DOCUMENT NUMBER: 137:145588
 TITLE: Proteoglycan compositions for treatment of inflammatory conditions
 INVENTOR(S): Theoharides, Theoharis C.
 PATENT ASSIGNEE(S): USA
 SOURCE: PCT Int. Appl., 21 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060393	A2	20020808	WO 2002-US476	20020103
WO 2002060393	A3	20030320		
WO 2002060393	B1	20031127		
W: AU, CA, JP, MX, NZ, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 2002176902	A1	20021128	US 2001-771669	20010130
EP 1365777	A2	20031203	EP 2002-705707	20020103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
US 2003099732	A1	20030529	US 2002-329386	20021227
US 6635625	B2	20031021		
US 2003104087	A1	20030605	US 2002-329366	20021227
US 6645482	B2	20031111		
US 2003104088	A1	20030605	US 2002-329367	20021227
US 6624148	B2	20030923		
US 2003113392	A1	20030619	US 2002-329387	20021227
US 6641806	B2	20031104		
US 2004005355	A1	20040108	US 2003-610909	20030702
US 2004043087	A1	20040304	US 2003-652312	20030828

PRIORITY APPLN. INFO.:

US 2001-771669 A2 20010130
 US 1998-56707 A3 19980408
 WO 2002-US476 W 20020103

AB Compns. with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomols. from the activated mast cells, composed of a heavily sulfated, non-bovine proteoglycan such as **shark cartilage** chondroitin sulfate C, and one or more of a hexosamine sulfate such as D-glucosamine sulfate, a flavone such as quercetin, an unrefined kernel olive oil that increases absorption of these compns. in various routes of administration, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, caffeine, and a polyamine. For example, a composition for protecting against cardiovascular disease, in the form of capsule to be taken 2 capsules orally 2-3 times per day, contained chondroitin sulfate 50 mg, kaempferol 100 mg, S-adenosylmethionine 50 mg, niacin 100 mg, and unrefined kernel olive oil 900-1200 mg.

L11 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:960660 CAPLUS
 DOCUMENT NUMBER: 138:19488
 TITLE: Method and pharmaceutical compositions using anti-microtubule agents for treating multiple

sclerotic and other inflammatory diseases
 INVENTOR(S): Hunter, William L.
 PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Can.
 SOURCE: U.S., 180 pp., Cont.-in-part of U.S. Appl. 2002
 37,919.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6495579	B1	20021217	US 1998-88546	19980601
US 2002037919	A1	20020328	US 1997-980549	19971201
US 6515016	B2	20030204		
EP 1070502	A2	20010124	EP 2000-123557	19971202
EP 1070502	A3	20011017		
EP 1070502	B1	20030604		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1090637	A2	20010411	EP 2000-123537	19971202
EP 1090637	A3	20010912		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1092433	A2	20010418	EP 2000-123534	19971202
EP 1092433	A3	20010912		
EP 1092433	B1	20030806		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002226399	A2	20020814	JP 2001-401899	19971202
WO 9962510	A2	19991209	WO 1999-CA464	19990601
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002013298	A1	20020131	US 1999-368463	19990804
US 2002183380	A1	20021205	US 2002-67467	20020205
US 6689803	B2	20040210		
US 2003157187	A1	20030821	US 2002-172737	20020613
PRIORITY APPLN. INFO.:				
US 1996-32215P P 19961202				
US 1997-63087P P 19971024				
US 1997-980549 A2 19971201				
EP 1997-945697 A3 19971202				
JP 1998-524997 A3 19971202				
US 1998-88546 A 19980601				
US 1999-368463 B1 19990804				
US 1999-368871 A1 19990804				
AB Methods and compns. for treating or preventing inflammatory diseases, e.g. psoriasis or multiple sclerosis, are provided, comprising delivering to the site of inflammation an anti-microtubule agent (e.g. paclitaxel), or analog or derivative thereof.				
REFERENCE COUNT: 171 THERE ARE 171 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT				

L11 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:63838 CAPLUS
 DOCUMENT NUMBER: 134:120960
 TITLE: Green-lip mussel product compositions addressing

INVENTOR(S): inflammation and/or degenerative disorders
Hashmi, Syed Ziauddin; Leech, Wayne Frederick;
McIaren, Donald George; McSporran, Keith David
PATENT ASSIGNEE(S): Bomac Laboratories Limited, N. Z.
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005411	A1	20010125	WO 2000-NZ135	20000721
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
NZ 336856	A	20010330	NZ 1999-336856	19990721
AU 727355	B3	20001214	AU 2000-48775	20000721
JP 2003504408	T2	20030204	JP 2001-510466	20000721
AU 761829	B2	20030612	AU 2000-63257	20000721
EP 1408999	A1	20040421	EP 2000-950109	20000721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				

PRIORITY APPLN. INFO.: NZ 1999-336856 A 19990721
NZ 1999-500630 A 19991027
NZ 2000-505875 A 20000721
WO 2000-NZ135 W 20000721

AB The present invention is directed to compns. for primarily addressing degenerative complaints, in particular joint related conditions, such as **arthritis** and rheumatism, in which there may also be associated inflammation. Other potential uses are also discussed, as well as prophylactic and curative applications. Preferred embodiments incorporate green-lip mussel products (particularly GLME) with **shark cartilage** or chondroitin compds. Plant and bark based antioxidants are employed in a number of embodiments. Dosage forms containing GLME, **shark cartilage**, vitamins and minerals are given. The compns. can be used especially for animals.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 13 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 2001131805 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11196523
TITLE: Surfing the Net--information on the World Wide Web for persons with **arthritis**: patient empowerment or patient deceit?.
COMMENT: Comment in: J Rheumatol. 2001 Jan;28(1):1-2. PubMed ID: 11196508
AUTHOR: Suarez-Almazor M E; Kendall C J; Dorgan M
CORPORATE SOURCE: Veteran Affairs Medical Center, Health Services, Research, Baylor College of Medicine, Houston, Texas 77030, USA.. mes@bcm.tmc.edu
SOURCE: Journal of rheumatology, (2001 Jan) 28 (1) 185-91. Journal code: 7501984. ISSN: 0315-162X.
PUB. COUNTRY: Canada
DOCUMENT TYPE: (EVALUATION STUDIES)
LANGUAGE: Journal; Article; (JOURNAL ARTICLE)
English

FILE SEGMENT: Priority Journals
ENTRY MONTH: 200103
ENTRY DATE: Entered STN: 20010404
Last Updated on STN: 20010404
Entered Medline: 20010301

AB OBJECTIVE: In the past few years access to the Internet has become readily available. Patients are increasingly seeking and obtaining health information through the Internet, most often the World Wide Web (WWW). We assessed the content, authorship, and scope of the information available on WWW in relation to rheumatoid arthritis. METHODS: In an attempt to replicate use by the average person, a broad search of the Internet was conducted for the phrase "rheumatoid arthritis" using WebCrawler, a commonly used search engine. All the "hits" were critically assessed after visiting and collecting information from the respective Web sites in relation to relevance, scope, authorship, type of publication, and financial objectives. RESULTS: The search returned 537 hits. We evaluated 531-2 did not exist, 2 could not be contacted, one was not in English, and one required a membership to access. The 531 hits originated from 388 Web sites. Only 198 (51%) were considered to be relevant and 7 (2%) were of doubtful relevance. Thirty-four (17%) were posted by an individual, 57 (28%) by a nonprofit organization, 104 (51%) by a profit industry, and 10 (5%) by universities. Ninety-one (44%) promoted alternative therapies, the most common including cetyl-myristoleate, colloidal minerals, Pycnogenol, shark cartilage, and Tahitian Noni. Of the 107 sites with financial interests, 76 (71%) promoted alternative medicine. The first 100 hits only identified about a third of the nonprofit organizations or university owned Web pages. CONCLUSION: Many sites easily accessed by consumers appear to be profit based companies advertising an alternative product claimed to be effective for many conditions. These findings emphasize the need for critical evaluation of Web site contents.

L11 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:731749 CAPLUS
DOCUMENT NUMBER: 131:332105
TITLE: Inhibition of angiogenesis by sea cucumber fractions containing sulfated polysaccharides
INVENTOR(S): Collin, Peter Donald
PATENT ASSIGNEE(S): Coastside Bio Resources, USA
SOURCE: U.S., 9 pp., Cont.-in-part of U.S. Ser. No. 692,175, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5985330	A	19991116	US 1997-880359	19970623
			US 1996-692175	19960805

PRIORITY APPLN. INFO.:

AB The present invention provides inhibition of angiogenesis in a warm-blooded animal by the administration of preps. isolated from the echinoderm sea cucumber (Class Holothuroidea). The preparation contains sulfated polysaccharides, sterol glycosides, saponins, lactones, peptides, protamines, glycogens, saccharides, and polysaccharides, and is useful as a therapeutic agent against malignant tumors and as a preventive or therapeutic drug against various diseases, such as rheumatoid arthritis, caused by vascular hyperplasia. Fucosylated chondroitin sulfate was extracted from the body wall of the sea cucumber *Ludwigothurea grisea* by papain digestion and tested for anti-angiogenic activity using the Chorioallantoic Membrane Assay (CAM) method. Sea cucumber fucosylated chondroitin sulfate showed good anti-angiogenic activity. The activity seen was nearly as high as that of the pos. control, hydrocortisone/heparin, and higher than that seen with

shark cartilage chondroitin-6-sulfate. A fraction termed B1000, consisting of sea cucumber epithelium, at 100 µg/mL decreased the ability of human melanoma tumor cell line C8161 to invade by the value of 63% inhibition.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:958356 CAPLUS
DOCUMENT NUMBER: 123:350289
TITLE: Dietary supplement for pain relief
INVENTOR(S): Woodward, Robert John
PATENT ASSIGNEE(S): UK
SOURCE: Brit. UK Pat. Appl., 9 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2286528	A1	19950823	GB 1994-3063	19940217
GB 2286528	B2	19980916		

PRIORITY APPLN. INFO.: GB 1994-3063 19940217

AB A dietary supplement containing sources of vitamins B3, B5, and/or B6, D-phenylalanine, glucosamine sulfate, and optionally mucopolysaccharides such as chondroitin sulfate and **shark cartilage** can provide relief of joint or muscular pain, e.g. **arthritis**. Thus, a tablet formulation contained pantothenic acid 100, **shark cartilage** 100, DL-phenylalanine 50, chondroitin sulfate 50, glucosamine sulfate 50 mg, and conventional tableting additives.

L11 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1993:623380 CAPLUS
DOCUMENT NUMBER: 119:223380
TITLE: The clinical significance on keratan sulfate levels of serum and synovial fluid in cases of osteoarthritis of the knee
AUTHOR(S): Mibe, Junya
CORPORATE SOURCE: Dep. Orthopedic Surg., Tokyo Med. Coll., Tokyo, Japan
SOURCE: Tokyo Ika Daigaku Zasshi (1993), 51(2), 141-52
CODEN: TIDZAH; ISSN: 0040-8905
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

AB Keratan sulfate (KS) is a sulfated glycosaminoglycan mostly found in the extracellular matrix of cartilage and is thought to be a useful marker of cartilage metabolism. The purpose of this study was to measure serum and synovial fluid KS levels and to clarify its clin. significance. Serum samples were obtained from 311 healthy adults and 93 cases of primary osteoarthritis (OA) of the knee. OA cases were subdivided into 3 groups; mild OA group, moderate OA group, and severe OA group. Specimens of synovial fluid of the knee were obtained from 79 OA cases (subdivided into the same 3 groups as above), 7 cases of acute traumatic synovitis (TS), and 22 cases of fresh medial collateral ligament injury (LI) of the knee. A modification of the competitive ELISA method of Thonar was employed, and the standard antigen was keratan polysulfate from **shark cartilage**. The normal serum KS level was 239.4 ± 55.7 ng/mL. There was no difference according to sex, but there was correlation with age ($r = 0.35$). The serum KS level of OA cases was 251.4 ± 64.5 ng/mL. There was no difference from normal subjects, or among each grade. The synovial fluid KS level of OA was 8.39 ± 7.78 µg/mL. There were differences among each grade; the mild OA group was 11.37 ± 9.34 µg/mL, the moderate OA group was 6.38 ± 3.60 µg/mL, and the severe OA group was 2.87 ± 1.21 µg/mL. When the mild OA group was

subdivided into acute stage and chronic stage, the KS level of the acute stage was higher than that of the chronic stage. Furthermore, the synovial fluid KS level of TS cases was $18.85 \pm 9.76 \mu\text{g/mL}$ while that of LI cases was $94.43 \pm 87.42 \mu\text{g/mL}$, therefore both cases were higher than the OA cases. It was concluded that the serum KS level reflects general factors. However, several cases which have high KS levels may suggest some abnormality in local cartilage metabolic activity. The synovial fluid KS level is associated with the grade of OA or severity of injury, reflecting local cartilage metabolism, especially catabolism.

L11 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1981:145330 CAPLUS
DOCUMENT NUMBER: 94:145330
TITLE: Cartilage extraction processes and products
INVENTOR(S): Balassa, Leslie L.
PATENT ASSIGNEE(S): Lescarden Ltd., USA
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8002501	A1	19801127	WO 1980-US503	19800502
W: JP, RO, SU				
RW: AT, CH, DE, FR, GB, LU, NL, SE				
US 4350682	A	19820921	US 1980-137547	19800404
EP 28254	A1	19810513	EP 1980-901098	19800502
EP 28254	B1	19840801		
R: AT, CH, DE, FR, GB, LU, NL, SE				
AT 8738	E	19840815	AT 1980-901098	19800502
CA 1140851	A1	19830208	CA 1980-351614	19800509
PRIORITY APPLN. INFO.:			US 1979-38051	19790511
			US 1980-137547	19800404
			EP 1980-901098	19800502
			WO 1980-US503	19800502

AB Cartilage exts. suitable for use in cosmetics, pharmaceuticals, and foods were prepared from bovine trachea, shark spinal column, or other animal source. Thus, 5 kg beef trachea and 50 g H₂O were cooked, in the absence of air, at 20 psig for 4 h with stirring at 20-60 rpm in a steam-jacketed vessel, the contents were filtered at 90°, and the fibrous matter was pressed (5 psi). The fluids were centrifuged to give 2500 g containing 840 g fat and 1550 g protein matter. The protein portion gelled on refrigeration, had a taste similar to meat extract, and could be used as a dietary supplement or as a pharmaceutical preparation

=>

---Logging off of STN---

Connection closed by remote host
END

Unable to generate the STN prompt.
Exiting the script...